ImprimisRx NJ is recalling 651 bottles of Timolol-Latanoprost and Timolol-Dorzolamide-Latanoprost preservative-free ophthalmic drops. These prescription eye drops, used primarily for treating glaucoma and ocular hypertension, were found to be subpotent, meaning they do not contain the full strength of the active ingredients required. Approximately 405 bottles of the two-drug combo and 246 bottles of the three-drug combo are affected. Consumers who use these medications should contact their healthcare provider or pharmacist for guidance, as the reduced strength may not effectively manage eye pressure.
The subpotent nature of these eye drops means the medication may not be effective in reducing intraocular pressure as intended. This could lead to poorly controlled glaucoma or ocular hypertension, potentially resulting in vision loss if the condition is not properly managed.
Pharmacy refund and healthcare consultation
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.